Your session is about to expire
← Back to Search
Hormone + Radiation Therapy for Metastatic Prostate Cancer
Study Summary
This trial is studying how well hormone therapy and radiation therapy work in treating patients with prostate cancer that has spread to other places in the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 3 trial • 637 Patients • NCT00884741Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any severe ongoing health issues or uncontrolled infections.I have had surgery to remove one or both of my testicles.I may have had hormone therapy for up to 36 weeks before joining this study.I have not had radiation for cancer that has spread.I understand the trial's nature and can give my written consent.I have not had chemotherapy for cancer that has spread.I can perform daily activities with little to no assistance.My tumor size was measured by a doctor within the last 28 days.I have or had brain metastases.I have had one non-chemotherapy treatment for my recurring or spreading cancer.My condition did not improve with hormone therapy using LHRH agonist.My prostate cancer is advanced with 5 or fewer spread sites.My doctor has approved my use of bisphosphonates.
- Group 1: Treatment (androgen therapy, radiation therapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What past researches have been conducted using Intensity-Modulated Radiation Therapy?
"Presently, 219 trials concerning Intensity-Modulated Radiation Therapy are in progress with 64 of them being Phase 3. While some clinical tests for this therapy take place in Duarte, California, 8,829 other centres offer the same kind of assessment."
What is the objective of this research endeavor?
"The primary measure of success for this trial, measured over a 40 week period, is the rate at which Prostate-specific Antigen (PSA) relapse. Secondary outcomes include time to progression and PSA response to treatment; with 36 weeks of androgen deprivation therapy being used as an estimate. Additionally, the feasibility of using helical tomotherapy image-guided radiation therapy will be assessed by determining what percentage of patients were able to receive IGRT via tomotherapy."
Are there any openings available for participants in this research?
"According to clinicaltrials.gov, this particular study has been inactive since April 4th 2022 and is not presently recruiting patients. However, there are currently 993 other trials searching for participants at the moment."
Has the FDA sanctioned Intensity-Modulated Radiation Therapy?
"With the available evidence, our team at Power believes Intensity-Modulated Radiation Therapy is relatively safe and gave it a score of 2. This medical intervention has been studied in phase two trials that indicate safety but not efficacy yet."
In what type of medical cases is Intensity-Modulated Radiation Therapy typically recommended?
"Intensity-Modulated Radiation Therapy (IMRT) is often employed to treat cervical syndrome, minor burns, stage t2b prostate carcinoma and post-transplantation."
What is the aggregate size of participants in this experimental endeavor?
"This research initiative has concluded its recruitment period, as the study was last updated on April 4th 2022. However, for those still seeking to participate in a trial, 774 programs are recruiting patients with adenocarcinoma and 219 trials are enrolling individuals requiring Intensity-Modulated Radiation Therapy."
Is this experimental process a pioneering endeavor?
"Since the first clinical trial in 2000, sponsored by AstraZeneca and involving 600 participants, Intensity-Modulated Radiation Therapy has undergone extensive study. This work culminated with Phase 3 drug approval prior to its current state of 219 active studies spanning 56 countries and 1452 cities."
Share this study with friends
Copy Link
Messenger